PFKFB3
The PFK2 isoform PFKFB3 is highly expressed in several human cancers, including colon, prostate, breast, ovary, and thyroid.
Most PFK2 isoforms both generate and degrade F-2,6-bisP, which activates PFK1 to increase fl ux through glycolysis. PFKFB3 has no phosphatase activity and its kinase activity may be stimulated by several oncogenic events, further promoting glycolytic fl ux.
PHGDH
Genomic regions containing the PHGDH gene are amplifi ed in breast cancer and melanoma.
PHGDH overexpression not only increases serine synthetic pathway fl ux to sustain cell proliferation but also generates αKG.
PGAM1
PGAM1 is upregulated in colorectal cancer and hepatocellular carcinoma, likely due to TP53 loss.
PGAM1 balances intracellular 3-phosphoglycerate and 2-phosphoglycerate levels, which regulate oxidative pentose phosphate pathway and serine synthetic pathway activities, respectively.
PKM2
Many cancer cells express the M2 isoform of PK. Tyrosine kinase signaling, including phosphorylation at Y105, reduces enzyme activity.
Low PKM2 catalytic activity causes accumulation of upstream glycolytic intermediates, promoting diversion of 3-phosphoglycerate into the serine synthetic pathway.
FAS
Highly expressed in human cancer, FAS expression is associated with poor prognosis in breast and prostate cancer.
While precise functional consequences have not been elucidated, FAS catalyzes fatty acid synthesis to support de novo lipogenesis and is critical for cell growth.
IDH1
Somatic missense mutations at R132 are prevalent in glioma, acute myeloid leukemia, and other cancers and confer neomorphic enzyme activity converting αKG to 2HG.
2HG can act as a competitive antagonist of multiple αKG-dependent dioxygenase enzymes, including DNA 5-methylcytosine hydroxylase TET2 and Jumonji C histone demethylase enzymes. Increased DNA and histone methylation may be linked to impaired cell differentiation.
IDH2
Missense mutations at R172 (the analogous residue to IDH1 R132) as well as the non-analogous residue R140 can lead to elevated 2HG levels.
IDH2 mutations can recapitulate many of the effects of IDH1 mutations. However, IDH1 and IDH2 mutations are found with distinct frequencies across different cancers, suggestive of subtle biochemical differences.
Proliferating cells rewire their metabolism to support growth. Quiescent cells break down fuels such as glucose, glutamine, and fatty acids for complete oxidation to carbon dioxide through the tricarboxylic acid cycle (TCA cycle). The chemical energy of these fuels is harnessed by reducing electron carriers NAD + and FAD to NADH and FADH 2 , respectively. These high-energy electrons are used to generate large amounts of adenosine triphosphate (ATP) by the mitochondrial electron transport chain. In this manner, quiescent cells efficiently convert nutrients into energy to sustain basic cellular processes. In contrast, rapidly proliferating cells must generate the proteins, lipids, and nucleic acids necessary to create a daughter cell. Consequently, cells take up large amounts of nutrients such as glucose and glutamine that are used to support cell growth. Intermediates of glycolysis and the TCA cycle provide the building blocks for nucleic acids, amino acids, and fatty acids. Glutamine catabolism maintains a steady supply of nutrients into the TCA cycle (anaplerosis), thus preserving the TCA cycle integrity despite continual efflux of metabolites to support growth.
Anabolic Cell Growth
In order to grow and divide, cells must be able to synthesize nucleotides, proteins, and lipids from exogenous glucose, glutamine, and essential amino acids. The signaling pathways controlling nutrient uptake (shown in orange) are frequently activated in cancer and directly fuel anabolic pathways. In particular, the PI3K/Akt pathway regulates the import and retention of glucose, thus providing substrates for glycolysis and the biosynthetic pathways that rely on continual supply of glycolytic intermediates. mTOR, downstream of Akt signaling, regulates the rate of protein translation, fueled by the supply of charged tRNAs generated by amino acid uptake and biosynthesis. Similarly, MYC regulates several steps in glutamine uptake and catabolism, ensuring a steady supply of nitrogen for nucleotide biosynthesis and α-ketoglutarate to fuel the TCA cycle. In turn, intermediates of glycolysis and the TCA cycle are used to generate the three major macromolecules required for growth. Glycolytic intermediates can be metabolized through the pentose phosphate pathway to generate the ribose-5-phosphate that represents the critical sugar backbone for nucleic acids. The glycolytic intermediate 3-phosphoglycerate is metabolized by PHGDH to produce serine and glycine, which in turn can contribute to pools of nonessential amino acids to fuel protein synthesis. Serine and glycine metabolism can also contribute to the pool of one-carbon metabolites that support nucleotide biosynthesis. Citrate, generated by the TCA cycle and exported to the cytoplasm, provides the critical acetyl-CoA building blocks for fatty acid synthesis.
A large number of metabolic enzymes (highlighted in blue) are amplified, alternatively spliced, or mutated in the pathogenesis of cancer (see table) . These include alterations that increase flux through glycolysis (PFKFB3, PGAM1) or diversion of glycolytic intermediates to biosynthetic pathways (PHGDH). Tyrosine kinase signaling downstream of oncogenic events serves to inhibit PKM2, thereby decreasing the rate of terminal glycolysis and increasing the availability of upstream metabolites for biosynthetic pathways. High FAS expression promotes the synthesis of fatty acids that are required for lipid biogenesis. Mutations that impair the function of SDH and FH trigger accumulation of abnormal levels of succinate and fumarate, respectively. While wild-type IDH enzymes catalyze the oxidative decarboxylation of isocitrate to produce αKG, gain-of-function mutations in the two NADP + -dependent IDH enzymes, mitochondrial IDH2 and cytosolic IDH1, enable the enzymes to reduce αKG, forming high levels of 2-hydroxyglutarate. All three of these pathologically accumulated metabolites (blue ovals) can impair the ability of cells to carry out α-ketoglutarate-dependent processes, with implications for cell survival and differentiation. Together, these findings demonstrate that oncogenic events influence the pathways of nutrient uptake and critical nodes of metabolism in order to support anabolic growth. Common oncogenic events are shown in orange. Metabolites and metabolic enzymes whose level, expression, or activity is altered in cancer are shown in blue.
Abbreviations 2HG, 2-hydroxyglutarate; αKG, α-ketoglutarate; ACL, ATP-citrate lyase; ATP, adenosine triphosphate; F-2,6-bisP, fructose 2,6-bisphosphate; FAS, fatty acid synthase; FH, fumarate hydratase; *GLDC, glycine decarboxylase. Note that this reaction occurs in the mitochondrion; HIFα, hypoxia-inducible factor, alpha subunit; HKII, hexokinase 2; IDH1, isocitate dehydrogenase 1; IDH2, isocitrate dehydrogenase 2; LDHA, lactate dehydrogenase A; mTOR, mechanistic target of rapamycin; PFKFB3, phosphofructo-2-kinase/ fructose-2,6-bisphosphatase 3; PGAM1, phosphoglycerate mutase 1; PHGDH, phosphoglycerate dehydrogenase; PI3K, phosphoinositide 3-kinase; PKM2, pyruvate kinase M2; RTK, receptor tyrosine kinase; SDH, succinate dehydrogenase; THF, tetrahydrofolate; Tyr-K, tyrosine kinase.
